Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7451.091 | 0.9493 | 0.9519 | 2.1415 | |
HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7451.091 | 0.9878 | 0.9886 | 2.1415 | |
HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7451.091 | 1.0477 | 1.0440 | 2.1415 | |
HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7451.091 | 0.7508 | 0.7494 | 2.1415 | |
HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7451.091 | 0.0893 | -0.3525 | 2.1415 | |
HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7451.091 | 0.0269 | -0.6306 | 2.1415 | |
HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7451.091 | 0.0084 | -0.7850 | 2.1415 | |
HCC1937 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7453.091 | 0.9622 | 0.9521 | 1.5914 | |
HCC1937 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7453.091 | 0.9509 | 0.9377 | 1.5914 | |
HCC1937 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7453.091 | 0.9557 | 0.9438 | 1.5914 | |
HCC1937 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7453.091 | 0.9637 | 0.9540 | 1.5914 | |
HCC1937 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7453.091 | 0.9779 | 0.9721 | 1.5914 | |
HCC1937 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7453.091 | 0.9562 | 0.9445 | 1.5914 | |
HCC1937 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7453.091 | 0.6059 | 0.4598 | 1.5914 | |
HCC1937 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7453.091 | 0.0104 | -0.8866 | 1.5914 | |
HCC1937 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7453.091 | 0.0044 | -0.9340 | 1.5914 | |
HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7454.092 | 0.9076 | 0.8496 | 1.2402 | |
HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7454.092 | 0.8957 | 0.8300 | 1.2402 | |
HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7454.092 | 0.9483 | 0.9161 | 1.2402 | |
HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7454.092 | 0.9470 | 0.9141 | 1.2402 | |
HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7454.092 | 0.9007 | 0.8382 | 1.2402 | |
HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7454.092 | 0.8104 | 0.6882 | 1.2402 | |
HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7454.092 | 0.3919 | -0.0603 | 1.2402 | |
HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7454.092 | 0.0190 | -0.9181 | 1.2402 | |
HCC1954 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7454.092 | 0.0106 | -0.9487 | 1.2402 |